GT Biopharma, Inc. (GTBP)
SEC filings, insider trading & institutional ownership from EDGAR.
Institutions
13
$429.01M held
Latest filings
10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR
No filings are available yet.
Top holders
13F & 13D/G · latest quarter
| Holder | Filed | Value |
|---|---|---|
| Vanguard Capital Management | Aug 13, 2026 | $184.44M |
| GEODE CAPITAL MANAGEMENT, LLC | Aug 12, 2026 | $130.65M |
| NORTHERN TRUST CORP | Aug 13, 2026 | $36.95M |
| CITADEL ADVISORS LLC | May 15, 2026 | $27.00M |
| JANE STREET GROUP, LLC | Feb 12, 2026 | $20.43M |
GTBP's filings are public. The insight is one click away.
Scrutar's AI reads every GTBP filing and surfaces what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.
Red Flag Detection20+ forensic checks per filingRisk RadarYear-over-year changes in risk factorsFiling DNADisclosure quality scored across six dimensionsSupply Chain GraphCustomers, suppliers & competitors mapped
Analyze GTBP filingsNo credit cardAI reports included on the free plan
Never miss a GTBP filing.
Get an email when GTBP files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Aug 30, 2026Source: SEC EDGAR.